文献速递淋巴瘤造血干细胞移植与细胞治疗

预测经典霍奇金淋巴瘤自体干细胞移植后结局的预后模型

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2017-09-12

该研究对174例经典霍奇金淋巴瘤患者的245份肿瘤标本进行数字基因表达谱分析,其中71例有初诊和复发时活检,利用65例复发活检构建基于基因表达的移植后预后模型RHL30,并在两个独立队列中验证。RHL30可识别移植后结局较差的高危患者,其预后能力独立于临床预后标志和微环境成分。

要点

  • 24%的患者初诊与复发活检基因表达模式相关性差,提示生物学差异。
  • 基于复发标本构建的RHL30模型在两个独立外部验证队列中识别出移植后结局较差的高危亚组。
  • RHL30的预后能力独立于初诊和复发时报告的临床预后标志及免疫组化评估的微环境成分。

核心结论

  • 开发并验证了一种新的临床可应用的预后检测方法,可在首次复发时识别自体干细胞移植后结局不佳的患者。
  • 未来关键是在正电子发射断层扫描引导的疗效评估和不断演变的经典霍奇金淋巴瘤治疗格局中评估RHL30的临床用途。

研究设计与样本

  • 对来自174例经典霍奇金淋巴瘤患者的245份福尔马林固定石蜡包埋肿瘤标本进行数字基因表达谱分析,其中71例有初诊和复发时活检。
  • 使用65例患者复发活检的训练队列构建基于基因表达的移植后预后模型RHL30,并使用两个独立队列进行验证。

主要发现

  • 基因表达谱显示24%的患者初诊与复发活检之间表达模式相关性差,表明存在生物学差异。
  • 比较初诊与复发标本基因表达测量的预后能力表明,复发时捕获的生物学对移植后结局预测具有更优特性。
  • 使用复发标本开发的RHL30在两个独立外部验证队列中识别出移植后结局较差的高危患者亚组。
  • RHL30的预后能力独立于报告的临床预后标志(初诊和复发时)以及免疫组化评估的微环境成分。

关键数值与推荐

  • RHL30模型基于65例患者复发活检的基因表达数据构建。
  • RHL30在两个独立外部验证队列中识别出移植后结局较差的高危患者亚组。

临床怎么用

  • 作者认为,所开发并验证的预后检测方法可在首次复发时识别自体干细胞移植后结局不佳的患者。
  • 作者认为,未来关键是在正电子发射断层扫描引导的疗效评估和不断演变的经典霍奇金淋巴瘤治疗格局中评估RHL30的临床用途。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed digital gene expression profiling on a cohort of 245 formalin-fixed, paraffin-embedded tumor specimens from 174 patients with cHL, including 71 with biopsies taken at both primary diagnosis and relapse, to investigate temporal gene expression differences and associations with post-ASCT outcomes. Relapse biopsies from a training cohort of 65 patients were used to build a gene expression-based prognostic model of post-ASCT outcomes (RHL30), and two independent cohorts were used for validation. Results Gene expression profiling revealed that 24% of patients exhibited poorly correlated expression patterns between their biopsies taken at initial diagnosis and relapse, indicating biologic divergence. Comparative analysis of the prognostic power of gene expression measurements in primary versus relapse specimens demonstrated that the biology captured at the time of relapse contained superior properties for post-ASCT outcome prediction. We developed RHL30, using relapse specimens, which identified a subset of high-risk patients with inferior post-ASCT outcomes in two independent external validation cohorts. The prognostic power of RHL30 was independent of reported clinical prognostic markers (both at initial diagnosis and at relapse) and microenvironmental components as assessed by immunohistochemistry. Conclusion We have developed and validated a novel clinically applicable prognostic assay that at the time of first relapse identifies patients with unfavorable post-ASCT outcomes. Moving forward, it will be critical to evaluate the clinical use of RHL30 in the context of positron emission tomography-guided response assessment and the evolving cHL treatment landscape.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chan FC, Mottok A, Gerrie AS, et al. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. J Clin Oncol. 2017. PMID: 28898161. doi:10.1200/JCO.2017.72.7925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。